Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase NA 3Phase 4 2Phase 1/2 2Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Neoplasms, Plasma Cell 2Multiple Myeloma 2Infections 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Pneumococcal Vaccines × Clear all
NCT00046852 2019-11-04

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

University of Maryland, Baltimore

Phase 1/2 Completed
Plasma cell

Infections, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00499577 2014-01-10

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1/2 Completed
56 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡